NCT02564367 (S-1 adjuvant) is a Phase 1, PHASE2 clinical trial of S-1 in Adenocarcinoma,Stomach, sponsored by AIO-Studien-gGmbH.

Who is sponsoring NCT02564367?

NCT02564367 is sponsored by AIO-Studien-gGmbH.

What drugs are being tested in NCT02564367?

Interventions in NCT02564367: S-1.

What condition does NCT02564367 study?

NCT02564367 studies Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction.

Is NCT02564367 still recruiting?

NCT02564367 is currently completed. Last updated 29 April 2021.

Last reviewed 2021-04-29 · How we verify

NCT02564367: S-1 adjuvant

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction

Completed Phase 1, PHASE2 Last updated 29 April 2021

What this trial tests

Phase 1, PHASE2 trial testing S-1 in Adenocarcinoma,Stomach in 30 participants. Completed in 6 March 2020.

Timeline

6 October 2015

Primary endpoint
1 March 2019

6 March 2020

Quick facts

Lead sponsor	AIO-Studien-gGmbH
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	6 October 2015
Primary completion	1 March 2019
Estimated completion	6 March 2020
Sites	1 location across Germany

Drugs / interventions tested

S-1 — full drug profile →

Conditions studied

Adenocarcinoma,Stomach — all drugs for Adenocarcinoma,Stomach →
Adenocarcinoma, Esophagogastric Junction — all drugs for Adenocarcinoma, Esophagogastric Junction →

Sponsor

AIO-Studien-gGmbH — full company profile →

Who can join

18 and older, any sex, with Adenocarcinoma,Stomach or Adenocarcinoma, Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter trial in Germany: Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction with the aim to show the feasibility and tolerability of adjuvant S-1 treatment in Caucasian patients and to determine the recommended dose for the treatment regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of S-1

Trials testing the same drug.

NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07384234 — SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis · Phase 2 · not yet recruiting
NCT07243938 — Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · Phase 2 · not yet recruiting
NCT07018063 — Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · Phase 2 · not yet recruiting

Other AIO-Studien-gGmbH trials

Trials by the same sponsor.

NCT05510895 — Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer · Phase 2 · completed
NCT05190263 — Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma · completed
NCT04727541 — Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer · Phase 2 · terminated
NCT04172467 — Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients · completed
NCT04221529 — Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02564367 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AIO-Studien-gGmbH
Last refreshed: 29 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02564367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing